Eisai Fortifies Play With India-Specific Priced Fycompa
Executive Summary
Eisai expects products like Fycompa and Lenvima, backed by innovative price planks pivoted around improving patient access, to intensify growth in India. Fycompa now debuts at a sub-$1 per day pricing in India.
You may also be interested in...
Eisai Shrinks India Multiple Sclerosis Commercial Team
Eisai recalibrates sales and marketing efforts for Biogen’s multiple sclerosis portfolio in India, joining a growing list of foreign firms that appear to be rightsizing their commercial engine in an ultra-competitive market.
Interview: Eisai India Unit’s Pivotal Role As Japan Genericizes
Eisai India chief Dr. Sanjit Singh Lamba outlines the competitive edge that the Japanese group’s Indian site offers under the deal with Nichi-Iko; the site has also never “depended” on active pharmaceutical ingredients from China. In a wide-ranging interview with Scrip, Lamba also discusses recent quality compliance initiatives in India.
Indian Panel Nudges Eisai Towards Phase IV Compliance For Halaven
Eisai’s request to forego Phase IV studies for its anticancer, Halaven, has been turned down by an Indian expert panel, which has reminded the Japanese company of the conditional marketing authorization previously granted for the product. Eisai, for its part, now says it will follow the “necessary requirements” set out by the Indian regulator.